IC
VTGN icon

Ikarian Capital’s VistaGen Therapeutics VTGN Stock Holding History

Ikarian Capital’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$297K Hold
519,077
– – 0.02% 134
2025
Q4 		$344K Sell
519,077
-101,792
-16% -$368K 0.03% 145
2025
Q3 		$2.2M Buy
620,869
+19,166
+3% +$57.3K 0.22% 97
2025
Q2 		$1.2M Hold
601,703
– – 0.23% 79
2025
Q1 		$1.5M Buy
601,703
+524,087
+675% +$1.48M 0.19% 80
2024
Q4 		$229K Buy
+77,616
New +$218K 0.03% 147
2023
Q4 		– Sell
-229,100
Closed -$1.2M – 183
2023
Q3 		$1.2M Buy
+229,100
New +$1.02M 0.14% 96
2022
Q2 		– Sell
-17,040
Closed -$633K – 204
2022
Q1 		$633K Buy
17,040
+1,184
+7% +$51.6K 0.08% 117
2021
Q4 		$927K Sell
15,856
-4,167
-21% -$271K 0.14% 102
2021
Q3 		$1.65M Sell
20,023
-10,529
-34% -$915K 0.12% 134
2021
Q2 		$2.89M Sell
30,552
-65,646
-68% -$4.86M 0.23% 101
2021
Q1 		$6.15M Sell
96,198
-53,334
-36% -$3.56M 0.21% 108
2020
Q4 		$8.7M Buy
+149,532
New +$3.82M 0.38% 62

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Ikarian Capital's VTGN Position: Q1 2026 in Review

Ikarian Capital held its VistaGen Therapeutics (VTGN) position steady in Q1 2026 at 519,077 shares worth $297K. The position accounts for 0.02% of the portfolio, ranked #134.

Ikarian Capital first reported a position in VTGN in Q4 2020 and has held it in 13 quarters since. The position peaked at $8.7M in Q4 2020. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Ikarian Capital held 519,077 shares of VistaGen Therapeutics worth $297K as of Q1 2026.
  • Ikarian Capital left its VistaGen Therapeutics share count unchanged in Q1 2026.
  • VistaGen Therapeutics made up 0.02% of Ikarian Capital's portfolio in Q1 2026, its #134 holding.
  • Ikarian Capital first reported a position in VistaGen Therapeutics in Q4 2020 and has held it in 13 quarters since.
  • Ikarian Capital's VistaGen Therapeutics position peaked at $8.7M in Q4 2020.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.